Education/CredentialsFellowship : Thomas Jefferson University (Hematologic Research )Residency: Thomas Jefferson University Hospital (Internal Medicine)Medical Degree: Thomas Jefferson University, Jefferson Medical College Bachelor's Degree: Duquesne University (Chemistry) Board Certifications & LicensesAmerican Board of Internal Medicine (Hematology) (Certification Date: 1978-06-27)American Board of Internal Medicine (Certification Date: 1975-06-18) Contact Information Email palascje@ucmail.uc.edu Research InterestsHemophilia, Sickle Cell Disease, Hematology Oncology Clinical Interests HematologyAnemiaErythrocytosisHemochromotosisHemolysisHigh platlet countHigh red blood cellsHypgammaglobulinemiaImmunodeficiencyLeuckopeniaLeukocytosisLow platlet countLow red blood cellsLymphadenopathyNeutropeniaPancytopeniaPolycythemia veraThalassemiaThrombocytopenia Peer Reviewed Publications Agne, J L; Ahmad, N; Palascak, J E; Khaled, R; Karim, N A 2015. VWD type 2N (Normandy) in two sisters. Haemophilia : the official journal of the World Federation of Hemophilia, 21 3, e223-5Beg,M.S.; Komrokji,R.S.; Ahmed,K.; Safa,M.M. 2008. Oxaliplatin-induced immune mediated thrombocytopenia Cancer Chemotherapy and Pharmacology, , 1Atiq,M.; Safa,M. 2007. Recurrent hypoglycemia associated with poorly differentiated carcinoma of the liver American Journal of Clinical Oncology: Cancer Clinical Trials, 30 2, 213Jazieh,A.R.; Younas,A.; Safa,M.; Redmond,K.; Buncher,R.; Howington,J. 2007. Phase i clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer Cancer Investigation, 25 5, 294Nahleh,Z.A.; Srikantiah,R.; Safa,M.; Jazieh,A.-R.; Muhleman,A.; Komrokji,R. 2007. Male breast cancer in the veterans affairs population: a comparative analysis Cancer, 109 8, 1471Lowy,A.M.; Firdaus,I.; Roychowdhury,D.; Redmond,K.; Howington,J.A.; Sussman,J.J.; Safa,M.; Ahmad,S.A.; Reed,M.F.; Rose,P.; James,L.; Jazieh,A.R. 2006. A phase ii study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials, 29 6, 555Safa,M.; Jazieh,A.-R. 2006. Lack of a uniform approach to clinical research training for hematology oncology fellows Journal of Cancer Education, 21 3, 166Goedert,J.J.; Siegel,J.; Miller,K.; Lederman,M.M.; Thompson,A.; Browning,B.; Gamerman,S.; McRedmond,K.; Withycombe,J.; Gruppo,R.; Stack,G.; Lusher,J.; Percy,L. 2005. Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among persons with haemophilia, 2001-2003 Haemophilia, 11 5, 516Parameswaran,R.; Shapiro,A.D.; Gill,J.C.; Kessler,C.M.; Abshire,T.; Angiolillo,A.; Boggio,L.; Cohen,A.; DiMichele,D.; Hanna,W.; Hoots,K.; Hord,J.; Key,N.; Konkle,B.; Kouides,P.; Kurczynski,E.; Marks,P.; Palascak,J.; Pipe,S.; Ragni,M.; Rivard,G.; Shopnick,R.; Tarantino,M.; Valentino,L.; Watts,R.; White,G. 2005. Dose effect and efficacy of rfviia in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry Haemophilia, 11 2, 100Thompson,A.R.; Gill,J.C.; Ewenstein,B.M.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R. 2004. Successful treatment for patients with von willebrand disease undergoing urgent surgery using factor viii/vwf concentrate (humate-p®) Haemophilia, 10 1, 42Gill,J.C.; Ewenstein,B.M.; Thompson,A.R.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R.; Binder,M.; Charbel,F.; Cooper,B.; Cornell,N.; Czapek,E.; Eisenberg,P.; Ewenstein,B.; Garcia-Ortiz,S.; Gastineau,D.; Gill,J.; Heggie,G.; Heisel,M.; Joist,H.; Knupp,C.; Lewis,B.; Matthews,D.; McKenna,P.; Murukutla,S.; Palascak,J.; Penner,J.; Powell,J.; Ritter,H.; Francisco,R.; Shapiro,A.; Simpson,T.; Stanek,M.; Thompson,A.R.; Tongol,J.; Waterbury,L.; White,G.; Young,R. 2003. Successful treatment of urgent bleeding in von willebrand disease with factor viii/vwf concentrate (humate-p®): use of the ristocetin cofactor assay (vwf:rco) to measure potency and to guide therapy Haemophilia, 9 6, 688Safa,M.; Lower,E.E.; Hasselgren,P.O.; Hungness,E.S.; Gazder,P.; Aron,B.; Shaughnessy,E.A.; Yassin,R. 2002. Bilateral synchronous breast cancer and her-2/neu overexpression Breast Cancer Research and Treatment, 72 3, 195Hickman, M A; Bernstein, I L; Palascak, J E 2000. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 84 2, 262-3Hickman,M.A.; Bernstein,I.L.; Palascak,J.E. 2000. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran Annals of Allergy, Asthma and Immunology, 84 2, 262Hungness,E.S.; Safa,M.; Shaughnessy,E.A.; Aron,B.S.; Gazder,P.A.; Hawkins,H.H.; Lower,E.E.; Seeskin,C.; Yassin,R.S.; Hasselgren,P.-O. 2000. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts Surgery, 128 4, 702Yasin,Z.; Retzinger,G.; Palascak,J. 2000. Thrombosis refractory to urokinase in a patient with pnh and factor v leiden mutation. is there a role for plasmaphersis? Blood, 98 11 PART II, Yasin,Z.; Quick,D.; Thiagarajan,P.; Spoor,D.; Caraveo,J.; Palascak,J. 1999. Light-chain paraproteins with lupus anticoagulant activity American Journal of Hematology, 62 2, 99Erslev, A J; Palascak, J E; Shaikh, B S; Martinez, J 1998. Platelet kinetics in autosomal dominant macrothrombocytopenia. The Journal of laboratory and clinical medicine, 131 6, 488-95; discussion 4Erslev,A.J.; Palascak,J.E.; Shaikh,B.S.; Martinez,J. 1998. Platelet kinetics in autosomal dominant macrothrombocytopenia Journal of Laboratory and Clinical Medicine, 131 6, 488Franco,R.; Barker-Gear,R.; Silberstein,E.; Mayfield,G.; Weiner,M.; Palascak,J.; Green,R. 1992. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival Advances in Experimental Medicine and Biology, 326 , 325Cotto,M.A.; Lutomski,D.M.; Palascak,J.E.; Fant,W.K.; LaFrance,R.J. 1990. Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study Journal of Parenteral and Enteral Nutrition, 14 2, 201Martelo, O J; Palascak, J E 1988. Platelet dysfunction and bleeding associated with beta-lactam antibiotics. The Journal of infectious diseases, 157 5, 1100-1Martelo,O.J.; Palascak,J.E. 1988. Platelet dysfunction and bleeding associated with beta-lactam antibiotics. Journal of Infectious Diseases, 157 5, 1100Lutomski,D.M.; Palascak,J.E.; Bower,R.H. 1987. Warfarin resistance associated with intravenous lipid administration Journal of Parenteral and Enteral Nutrition, 11 3, 316Miller, M A; Palascak, J E; Thompson, M R; Martelo, O J 1985. A modified SDS agarose gel method for determining factor VIII von Willebrand factor multimers using commercially available reagents. Thrombosis research, 39 6, 777-80Miller,M.A.; Palascak,J.E.; Thompson,M.R. 1985. A modified sds agarose gel method for determining factor viii von willebrand factor multimers using commercially available reagents Thrombosis Research, 39 6, 777Martinez, J; Keane, P M; Gilman, P B; Palascak, J E 1983. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Annals of the New York Academy of Sciences, 408 , 388-96Martinez, J; MacDonald, K A; Palascak, J E 1983. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood, 61 6, 1196-202Martinez,J.; Keane,P.M.; Gilman,P.B.; Palascak,J.E. 1983. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease Annals of the New York Academy of Sciences, Vol. 408 , 388Martinez,J.; MacDonald,K.A.; Palascak,J.E. 1983. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains Blood, 61 6, 1196Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. The New England journal of medicine, 303 8, 421-5Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M 1980. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, 93 , 175-81Lusher,J.M.; Shapiro,S.S.; Palascak,J.E. 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor viii. a multicenter therapeutic trial New England Journal of Medicine, 303 8, 421Lusher,J.M.; Shapiro,S.S.; Palascak,J.E.; Rao,A.V.; Levine,P.H.; Blatt,P.M. 1980. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, 93 , 175Martinez, J; Palascak, J E; Kwasniak, D 1978. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. The Journal of clinical investigation, 61 2, 535-8Martinez,J.; Palascak,J.E.; Kwasniak,D. 1978. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease Journal of Clinical Investigation, 61 2, 535Martinez,J.; Palascak,J.; Peters,C. 1977. Functional and metabolic properties of human asialofibrinogen Journal of Laboratory and Clinical Medicine, 89 2, 367Palascak, J E; Martinez, J 1977. Dysfibrinogenemia associated with liver disease. The Journal of clinical investigation, 60 1, 89-95Palascak, J E; Shapiro, S R 1977. Anti-factor VIII anamnesis after factor IX complex. The New England journal of medicine, 297 25, 1403Palascak,J.E.; Martinez,J. 1977. Dysfibrinogenemia associated with liver disease Journal of Clinical Investigation, 60 1, 89Palascak,J.E.; Shapiro,S.R. 1977. Anti-factor viii anamnesis after factor ix complex. New England Journal of Medicine, 297 25, 1403Martinez, J; Palascak, J E; Peters, C L 1975. Proceedings: Functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, 34 1, 324Martinez,J.; Palascak,J.E.; Peters,C.L. 1975. Proceedings: functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, 34 1, 324Krauss J.S.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. 12-11-1980. Treatment of Hemophilia with Prothrombincomplex Concentrates New England Journal of Medicine, 303 24, 1418Franco R.;Barker-Gear R.;Silberstein E.;Mayfield G.;Weiner M.;Palascak J.;Green R. 12-01-1992. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased i Advances in Experimental Medicine and Biology, 326 , 325-331Yasin Z.;Quick D.;Thiagarajan P.;Spoor D.;Caraveo J.;Palascak J. 10-13-1999. Light-chain paraproteins with lupus anticoagulant activity American Journal of Hematology, 62 2, 99-102Goedert J.J.;Siegel J.;Miller K.;Lederman M.M.;Thompson A.;Browning B.;Gamerman S.;McRedmond K.;Withycombe J.;Gruppo R.;Stack G.;Lusher J.;Percy L.;Nugent D.;McDaniel M.;Manno C.;Butler R.;Wade A.;Angiolillo A.;Luban N.L.C.;Guelcher C.;Tarantino M.;Greer S.;Gill J.;Nelson J.;White G.;Fried M.;Grimsley A.L.;DiMichele D.;Goldberg I.;French J.;Hibner S.;Steinberg J.;Faust S.;Key N.;Hannemann V.;Kessler C.M.;Lee A.E.;Eyster M.E.;Galli K.;Jenkins G.;Bernstein Z.P.;Belling L.;Shapiro A.;Halley M.;Noblet P.;Jardine L.;Laudenbach L.;Lipton R.;Pece C.;Leissinger C.A.;Schmidt C.;Carr M.;Nolte M.;Manco-Johnson M.;Giambartolomei S.;Rubin S.H.;Belliveau D.;Aledort L.;McCarthy J.;Lemons R.;Bleak S.;Kraut E.;Witkoff L.;Sexauer C.;Kiplinger F.;Thompson A.;Cooper C.;Britton H.;Cobb K.;Reimers H.J.;Bagato J.A.;Powell J.S.;Herr M.;Scott K.;Hutter J.;Damiano M.L.;Navarro W.;Roth J.;Palascak J.;Sherman K.;Heffner M.;DiPaolo J.;Lammer M.;Iyer R.;Matthew P.;Schwartz M.;Konkle B.;Vijayanathan N.;Dugdale M.;Lilley D.;Hoots K.;Brown D.;Ullman M.;Neff A.;Klintworth S.;Sabio H.;Smith A.;Karafoulidou A. 09-01-2005. Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among Haemophilia, 11 5, 516-528Lusher J.M.;Shapiro S.S.;Palascak J.E.;Rao A.V.;Levine P.H.;Blatt P.M. 08-21-1980. Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII: A Multi New England Journal of Medicine, 303 8, 421-425Manco-Johnson M.J.;Bomgaars L.;Palascak J.;Shapiro A.;Geil J.;Fritsch S.;Pavlova B.G.;Gelmont D. 07-01-2016. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in Thrombosis and Haemostasis, 116 1, 58-68Sherman K.E.;Ke R.;Rouster S.D.;Abdel-Hameed E.A.;Park C.;Palascak J.;Perelson A.S. 07-01-2016. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs Haemophilia, 22 4, 543-548Tsuang W.;Navaneethan U.;Ruiz L.;Palascak J.B.;Gelrud A. 04-01-2009. Hypertriglyceridemic pancreatitis: Presentation and management American Journal of Gastroenterology, 104 4, 984-991Abildgaard C.F.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. 03-12-1981. Hazards of Prothrombin-Complex Concentrates in Treatment of Hemophilia New England Journal of Medicine, 304 11, 670-671Parameswaran R.;Shapiro A.;Gill J.;Kessler C.;Abshire T.;Angiolillo A.;Boggio L.;Cohen A.;DiMichele D.;Hanna W.;Hoots K.;Hord J.;Key N.;Konkle B.;Kouides P.;Kurczynski E.;Marks P.;Palascak J.;Pipe S.;Ragni M.;Rivard G.;Shopnick R.;Tarantino M.;Valentino L.;Watts R.;White G. 03-01-2005. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysi Haemophilia, 11 2, 100-106Thompson A.R.;Gill J.C.;Ewenstein B.M.;Mueller-Velten G.;Schwartz B.A.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Bobrow S.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Green D.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Silver B.;Simpson T.;Stanek M.;Thompson A.R.;Tongol J.;Waterbury L.;White G.;Young R. 01-01-2004. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor Haemophilia, 10 1, 42-51Gill J.;Ewenstein B.;Thompson A.;Mueller-Velten G.;Schwartz B.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Simpson T.;Stanek M.;Thompson A.;Tongol J.;Waterbury L.;White G.;Young R. 01-01-2003. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate ( Haemophilia, 9 6, 688-695Martinez J.;Palascak J.;Peters C. 01-01-1977. Functional and metabolic properties of human asialofibrinogen The Journal of Laboratory and Clinical Medicine, 89 2, 367-377Cotto, M A; Lutomski, D M; Palascak, J E; Fant, W K; LaFrance, R J . Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study. JPEN. Journal of parenteral and enteral nutrition, 14 2, 201-3Lutomski, D M; Palascak, J E; Bower, R H . Warfarin resistance associated with intravenous lipid administration. JPEN. Journal of parenteral and enteral nutrition, 11 3, 316-8
Clinical Interests HematologyAnemiaErythrocytosisHemochromotosisHemolysisHigh platlet countHigh red blood cellsHypgammaglobulinemiaImmunodeficiencyLeuckopeniaLeukocytosisLow platlet countLow red blood cellsLymphadenopathyNeutropeniaPancytopeniaPolycythemia veraThalassemiaThrombocytopenia
Peer Reviewed Publications Agne, J L; Ahmad, N; Palascak, J E; Khaled, R; Karim, N A 2015. VWD type 2N (Normandy) in two sisters. Haemophilia : the official journal of the World Federation of Hemophilia, 21 3, e223-5Beg,M.S.; Komrokji,R.S.; Ahmed,K.; Safa,M.M. 2008. Oxaliplatin-induced immune mediated thrombocytopenia Cancer Chemotherapy and Pharmacology, , 1Atiq,M.; Safa,M. 2007. Recurrent hypoglycemia associated with poorly differentiated carcinoma of the liver American Journal of Clinical Oncology: Cancer Clinical Trials, 30 2, 213Jazieh,A.R.; Younas,A.; Safa,M.; Redmond,K.; Buncher,R.; Howington,J. 2007. Phase i clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer Cancer Investigation, 25 5, 294Nahleh,Z.A.; Srikantiah,R.; Safa,M.; Jazieh,A.-R.; Muhleman,A.; Komrokji,R. 2007. Male breast cancer in the veterans affairs population: a comparative analysis Cancer, 109 8, 1471Lowy,A.M.; Firdaus,I.; Roychowdhury,D.; Redmond,K.; Howington,J.A.; Sussman,J.J.; Safa,M.; Ahmad,S.A.; Reed,M.F.; Rose,P.; James,L.; Jazieh,A.R. 2006. A phase ii study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials, 29 6, 555Safa,M.; Jazieh,A.-R. 2006. Lack of a uniform approach to clinical research training for hematology oncology fellows Journal of Cancer Education, 21 3, 166Goedert,J.J.; Siegel,J.; Miller,K.; Lederman,M.M.; Thompson,A.; Browning,B.; Gamerman,S.; McRedmond,K.; Withycombe,J.; Gruppo,R.; Stack,G.; Lusher,J.; Percy,L. 2005. Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among persons with haemophilia, 2001-2003 Haemophilia, 11 5, 516Parameswaran,R.; Shapiro,A.D.; Gill,J.C.; Kessler,C.M.; Abshire,T.; Angiolillo,A.; Boggio,L.; Cohen,A.; DiMichele,D.; Hanna,W.; Hoots,K.; Hord,J.; Key,N.; Konkle,B.; Kouides,P.; Kurczynski,E.; Marks,P.; Palascak,J.; Pipe,S.; Ragni,M.; Rivard,G.; Shopnick,R.; Tarantino,M.; Valentino,L.; Watts,R.; White,G. 2005. Dose effect and efficacy of rfviia in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry Haemophilia, 11 2, 100Thompson,A.R.; Gill,J.C.; Ewenstein,B.M.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R. 2004. Successful treatment for patients with von willebrand disease undergoing urgent surgery using factor viii/vwf concentrate (humate-p®) Haemophilia, 10 1, 42Gill,J.C.; Ewenstein,B.M.; Thompson,A.R.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R.; Binder,M.; Charbel,F.; Cooper,B.; Cornell,N.; Czapek,E.; Eisenberg,P.; Ewenstein,B.; Garcia-Ortiz,S.; Gastineau,D.; Gill,J.; Heggie,G.; Heisel,M.; Joist,H.; Knupp,C.; Lewis,B.; Matthews,D.; McKenna,P.; Murukutla,S.; Palascak,J.; Penner,J.; Powell,J.; Ritter,H.; Francisco,R.; Shapiro,A.; Simpson,T.; Stanek,M.; Thompson,A.R.; Tongol,J.; Waterbury,L.; White,G.; Young,R. 2003. Successful treatment of urgent bleeding in von willebrand disease with factor viii/vwf concentrate (humate-p®): use of the ristocetin cofactor assay (vwf:rco) to measure potency and to guide therapy Haemophilia, 9 6, 688Safa,M.; Lower,E.E.; Hasselgren,P.O.; Hungness,E.S.; Gazder,P.; Aron,B.; Shaughnessy,E.A.; Yassin,R. 2002. Bilateral synchronous breast cancer and her-2/neu overexpression Breast Cancer Research and Treatment, 72 3, 195Hickman, M A; Bernstein, I L; Palascak, J E 2000. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 84 2, 262-3Hickman,M.A.; Bernstein,I.L.; Palascak,J.E. 2000. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran Annals of Allergy, Asthma and Immunology, 84 2, 262Hungness,E.S.; Safa,M.; Shaughnessy,E.A.; Aron,B.S.; Gazder,P.A.; Hawkins,H.H.; Lower,E.E.; Seeskin,C.; Yassin,R.S.; Hasselgren,P.-O. 2000. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts Surgery, 128 4, 702Yasin,Z.; Retzinger,G.; Palascak,J. 2000. Thrombosis refractory to urokinase in a patient with pnh and factor v leiden mutation. is there a role for plasmaphersis? Blood, 98 11 PART II, Yasin,Z.; Quick,D.; Thiagarajan,P.; Spoor,D.; Caraveo,J.; Palascak,J. 1999. Light-chain paraproteins with lupus anticoagulant activity American Journal of Hematology, 62 2, 99Erslev, A J; Palascak, J E; Shaikh, B S; Martinez, J 1998. Platelet kinetics in autosomal dominant macrothrombocytopenia. The Journal of laboratory and clinical medicine, 131 6, 488-95; discussion 4Erslev,A.J.; Palascak,J.E.; Shaikh,B.S.; Martinez,J. 1998. Platelet kinetics in autosomal dominant macrothrombocytopenia Journal of Laboratory and Clinical Medicine, 131 6, 488Franco,R.; Barker-Gear,R.; Silberstein,E.; Mayfield,G.; Weiner,M.; Palascak,J.; Green,R. 1992. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival Advances in Experimental Medicine and Biology, 326 , 325Cotto,M.A.; Lutomski,D.M.; Palascak,J.E.; Fant,W.K.; LaFrance,R.J. 1990. Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study Journal of Parenteral and Enteral Nutrition, 14 2, 201Martelo, O J; Palascak, J E 1988. Platelet dysfunction and bleeding associated with beta-lactam antibiotics. The Journal of infectious diseases, 157 5, 1100-1Martelo,O.J.; Palascak,J.E. 1988. Platelet dysfunction and bleeding associated with beta-lactam antibiotics. Journal of Infectious Diseases, 157 5, 1100Lutomski,D.M.; Palascak,J.E.; Bower,R.H. 1987. Warfarin resistance associated with intravenous lipid administration Journal of Parenteral and Enteral Nutrition, 11 3, 316Miller, M A; Palascak, J E; Thompson, M R; Martelo, O J 1985. A modified SDS agarose gel method for determining factor VIII von Willebrand factor multimers using commercially available reagents. Thrombosis research, 39 6, 777-80Miller,M.A.; Palascak,J.E.; Thompson,M.R. 1985. A modified sds agarose gel method for determining factor viii von willebrand factor multimers using commercially available reagents Thrombosis Research, 39 6, 777Martinez, J; Keane, P M; Gilman, P B; Palascak, J E 1983. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Annals of the New York Academy of Sciences, 408 , 388-96Martinez, J; MacDonald, K A; Palascak, J E 1983. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood, 61 6, 1196-202Martinez,J.; Keane,P.M.; Gilman,P.B.; Palascak,J.E. 1983. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease Annals of the New York Academy of Sciences, Vol. 408 , 388Martinez,J.; MacDonald,K.A.; Palascak,J.E. 1983. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains Blood, 61 6, 1196Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. The New England journal of medicine, 303 8, 421-5Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M 1980. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, 93 , 175-81Lusher,J.M.; Shapiro,S.S.; Palascak,J.E. 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor viii. a multicenter therapeutic trial New England Journal of Medicine, 303 8, 421Lusher,J.M.; Shapiro,S.S.; Palascak,J.E.; Rao,A.V.; Levine,P.H.; Blatt,P.M. 1980. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, 93 , 175Martinez, J; Palascak, J E; Kwasniak, D 1978. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. The Journal of clinical investigation, 61 2, 535-8Martinez,J.; Palascak,J.E.; Kwasniak,D. 1978. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease Journal of Clinical Investigation, 61 2, 535Martinez,J.; Palascak,J.; Peters,C. 1977. Functional and metabolic properties of human asialofibrinogen Journal of Laboratory and Clinical Medicine, 89 2, 367Palascak, J E; Martinez, J 1977. Dysfibrinogenemia associated with liver disease. The Journal of clinical investigation, 60 1, 89-95Palascak, J E; Shapiro, S R 1977. Anti-factor VIII anamnesis after factor IX complex. The New England journal of medicine, 297 25, 1403Palascak,J.E.; Martinez,J. 1977. Dysfibrinogenemia associated with liver disease Journal of Clinical Investigation, 60 1, 89Palascak,J.E.; Shapiro,S.R. 1977. Anti-factor viii anamnesis after factor ix complex. New England Journal of Medicine, 297 25, 1403Martinez, J; Palascak, J E; Peters, C L 1975. Proceedings: Functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, 34 1, 324Martinez,J.; Palascak,J.E.; Peters,C.L. 1975. Proceedings: functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, 34 1, 324Krauss J.S.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. 12-11-1980. Treatment of Hemophilia with Prothrombincomplex Concentrates New England Journal of Medicine, 303 24, 1418Franco R.;Barker-Gear R.;Silberstein E.;Mayfield G.;Weiner M.;Palascak J.;Green R. 12-01-1992. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased i Advances in Experimental Medicine and Biology, 326 , 325-331Yasin Z.;Quick D.;Thiagarajan P.;Spoor D.;Caraveo J.;Palascak J. 10-13-1999. Light-chain paraproteins with lupus anticoagulant activity American Journal of Hematology, 62 2, 99-102Goedert J.J.;Siegel J.;Miller K.;Lederman M.M.;Thompson A.;Browning B.;Gamerman S.;McRedmond K.;Withycombe J.;Gruppo R.;Stack G.;Lusher J.;Percy L.;Nugent D.;McDaniel M.;Manno C.;Butler R.;Wade A.;Angiolillo A.;Luban N.L.C.;Guelcher C.;Tarantino M.;Greer S.;Gill J.;Nelson J.;White G.;Fried M.;Grimsley A.L.;DiMichele D.;Goldberg I.;French J.;Hibner S.;Steinberg J.;Faust S.;Key N.;Hannemann V.;Kessler C.M.;Lee A.E.;Eyster M.E.;Galli K.;Jenkins G.;Bernstein Z.P.;Belling L.;Shapiro A.;Halley M.;Noblet P.;Jardine L.;Laudenbach L.;Lipton R.;Pece C.;Leissinger C.A.;Schmidt C.;Carr M.;Nolte M.;Manco-Johnson M.;Giambartolomei S.;Rubin S.H.;Belliveau D.;Aledort L.;McCarthy J.;Lemons R.;Bleak S.;Kraut E.;Witkoff L.;Sexauer C.;Kiplinger F.;Thompson A.;Cooper C.;Britton H.;Cobb K.;Reimers H.J.;Bagato J.A.;Powell J.S.;Herr M.;Scott K.;Hutter J.;Damiano M.L.;Navarro W.;Roth J.;Palascak J.;Sherman K.;Heffner M.;DiPaolo J.;Lammer M.;Iyer R.;Matthew P.;Schwartz M.;Konkle B.;Vijayanathan N.;Dugdale M.;Lilley D.;Hoots K.;Brown D.;Ullman M.;Neff A.;Klintworth S.;Sabio H.;Smith A.;Karafoulidou A. 09-01-2005. Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among Haemophilia, 11 5, 516-528Lusher J.M.;Shapiro S.S.;Palascak J.E.;Rao A.V.;Levine P.H.;Blatt P.M. 08-21-1980. Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII: A Multi New England Journal of Medicine, 303 8, 421-425Manco-Johnson M.J.;Bomgaars L.;Palascak J.;Shapiro A.;Geil J.;Fritsch S.;Pavlova B.G.;Gelmont D. 07-01-2016. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in Thrombosis and Haemostasis, 116 1, 58-68Sherman K.E.;Ke R.;Rouster S.D.;Abdel-Hameed E.A.;Park C.;Palascak J.;Perelson A.S. 07-01-2016. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs Haemophilia, 22 4, 543-548Tsuang W.;Navaneethan U.;Ruiz L.;Palascak J.B.;Gelrud A. 04-01-2009. Hypertriglyceridemic pancreatitis: Presentation and management American Journal of Gastroenterology, 104 4, 984-991Abildgaard C.F.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. 03-12-1981. Hazards of Prothrombin-Complex Concentrates in Treatment of Hemophilia New England Journal of Medicine, 304 11, 670-671Parameswaran R.;Shapiro A.;Gill J.;Kessler C.;Abshire T.;Angiolillo A.;Boggio L.;Cohen A.;DiMichele D.;Hanna W.;Hoots K.;Hord J.;Key N.;Konkle B.;Kouides P.;Kurczynski E.;Marks P.;Palascak J.;Pipe S.;Ragni M.;Rivard G.;Shopnick R.;Tarantino M.;Valentino L.;Watts R.;White G. 03-01-2005. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysi Haemophilia, 11 2, 100-106Thompson A.R.;Gill J.C.;Ewenstein B.M.;Mueller-Velten G.;Schwartz B.A.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Bobrow S.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Green D.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Silver B.;Simpson T.;Stanek M.;Thompson A.R.;Tongol J.;Waterbury L.;White G.;Young R. 01-01-2004. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor Haemophilia, 10 1, 42-51Gill J.;Ewenstein B.;Thompson A.;Mueller-Velten G.;Schwartz B.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Simpson T.;Stanek M.;Thompson A.;Tongol J.;Waterbury L.;White G.;Young R. 01-01-2003. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate ( Haemophilia, 9 6, 688-695Martinez J.;Palascak J.;Peters C. 01-01-1977. Functional and metabolic properties of human asialofibrinogen The Journal of Laboratory and Clinical Medicine, 89 2, 367-377Cotto, M A; Lutomski, D M; Palascak, J E; Fant, W K; LaFrance, R J . Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study. JPEN. Journal of parenteral and enteral nutrition, 14 2, 201-3Lutomski, D M; Palascak, J E; Bower, R H . Warfarin resistance associated with intravenous lipid administration. JPEN. Journal of parenteral and enteral nutrition, 11 3, 316-8
Agne, J L; Ahmad, N; Palascak, J E; Khaled, R; Karim, N A 2015. VWD type 2N (Normandy) in two sisters. Haemophilia : the official journal of the World Federation of Hemophilia, 21 3, e223-5Beg,M.S.; Komrokji,R.S.; Ahmed,K.; Safa,M.M. 2008. Oxaliplatin-induced immune mediated thrombocytopenia Cancer Chemotherapy and Pharmacology, , 1Atiq,M.; Safa,M. 2007. Recurrent hypoglycemia associated with poorly differentiated carcinoma of the liver American Journal of Clinical Oncology: Cancer Clinical Trials, 30 2, 213Jazieh,A.R.; Younas,A.; Safa,M.; Redmond,K.; Buncher,R.; Howington,J. 2007. Phase i clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer Cancer Investigation, 25 5, 294Nahleh,Z.A.; Srikantiah,R.; Safa,M.; Jazieh,A.-R.; Muhleman,A.; Komrokji,R. 2007. Male breast cancer in the veterans affairs population: a comparative analysis Cancer, 109 8, 1471Lowy,A.M.; Firdaus,I.; Roychowdhury,D.; Redmond,K.; Howington,J.A.; Sussman,J.J.; Safa,M.; Ahmad,S.A.; Reed,M.F.; Rose,P.; James,L.; Jazieh,A.R. 2006. A phase ii study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials, 29 6, 555Safa,M.; Jazieh,A.-R. 2006. Lack of a uniform approach to clinical research training for hematology oncology fellows Journal of Cancer Education, 21 3, 166Goedert,J.J.; Siegel,J.; Miller,K.; Lederman,M.M.; Thompson,A.; Browning,B.; Gamerman,S.; McRedmond,K.; Withycombe,J.; Gruppo,R.; Stack,G.; Lusher,J.; Percy,L. 2005. Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among persons with haemophilia, 2001-2003 Haemophilia, 11 5, 516Parameswaran,R.; Shapiro,A.D.; Gill,J.C.; Kessler,C.M.; Abshire,T.; Angiolillo,A.; Boggio,L.; Cohen,A.; DiMichele,D.; Hanna,W.; Hoots,K.; Hord,J.; Key,N.; Konkle,B.; Kouides,P.; Kurczynski,E.; Marks,P.; Palascak,J.; Pipe,S.; Ragni,M.; Rivard,G.; Shopnick,R.; Tarantino,M.; Valentino,L.; Watts,R.; White,G. 2005. Dose effect and efficacy of rfviia in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry Haemophilia, 11 2, 100Thompson,A.R.; Gill,J.C.; Ewenstein,B.M.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R. 2004. Successful treatment for patients with von willebrand disease undergoing urgent surgery using factor viii/vwf concentrate (humate-p®) Haemophilia, 10 1, 42Gill,J.C.; Ewenstein,B.M.; Thompson,A.R.; Mueller-Velten,G.; Schwartz,B.A.; Abshire,T.; Ambinder,R.; Angiolillo,A.; Arkel,Y.; Beardsley,D.; Benjamin,R.; Binder,M.; Charbel,F.; Cooper,B.; Cornell,N.; Czapek,E.; Eisenberg,P.; Ewenstein,B.; Garcia-Ortiz,S.; Gastineau,D.; Gill,J.; Heggie,G.; Heisel,M.; Joist,H.; Knupp,C.; Lewis,B.; Matthews,D.; McKenna,P.; Murukutla,S.; Palascak,J.; Penner,J.; Powell,J.; Ritter,H.; Francisco,R.; Shapiro,A.; Simpson,T.; Stanek,M.; Thompson,A.R.; Tongol,J.; Waterbury,L.; White,G.; Young,R. 2003. Successful treatment of urgent bleeding in von willebrand disease with factor viii/vwf concentrate (humate-p®): use of the ristocetin cofactor assay (vwf:rco) to measure potency and to guide therapy Haemophilia, 9 6, 688Safa,M.; Lower,E.E.; Hasselgren,P.O.; Hungness,E.S.; Gazder,P.; Aron,B.; Shaughnessy,E.A.; Yassin,R. 2002. Bilateral synchronous breast cancer and her-2/neu overexpression Breast Cancer Research and Treatment, 72 3, 195Hickman, M A; Bernstein, I L; Palascak, J E 2000. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 84 2, 262-3Hickman,M.A.; Bernstein,I.L.; Palascak,J.E. 2000. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran Annals of Allergy, Asthma and Immunology, 84 2, 262Hungness,E.S.; Safa,M.; Shaughnessy,E.A.; Aron,B.S.; Gazder,P.A.; Hawkins,H.H.; Lower,E.E.; Seeskin,C.; Yassin,R.S.; Hasselgren,P.-O. 2000. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts Surgery, 128 4, 702Yasin,Z.; Retzinger,G.; Palascak,J. 2000. Thrombosis refractory to urokinase in a patient with pnh and factor v leiden mutation. is there a role for plasmaphersis? Blood, 98 11 PART II, Yasin,Z.; Quick,D.; Thiagarajan,P.; Spoor,D.; Caraveo,J.; Palascak,J. 1999. Light-chain paraproteins with lupus anticoagulant activity American Journal of Hematology, 62 2, 99Erslev, A J; Palascak, J E; Shaikh, B S; Martinez, J 1998. Platelet kinetics in autosomal dominant macrothrombocytopenia. The Journal of laboratory and clinical medicine, 131 6, 488-95; discussion 4Erslev,A.J.; Palascak,J.E.; Shaikh,B.S.; Martinez,J. 1998. Platelet kinetics in autosomal dominant macrothrombocytopenia Journal of Laboratory and Clinical Medicine, 131 6, 488Franco,R.; Barker-Gear,R.; Silberstein,E.; Mayfield,G.; Weiner,M.; Palascak,J.; Green,R. 1992. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival Advances in Experimental Medicine and Biology, 326 , 325Cotto,M.A.; Lutomski,D.M.; Palascak,J.E.; Fant,W.K.; LaFrance,R.J. 1990. Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study Journal of Parenteral and Enteral Nutrition, 14 2, 201Martelo, O J; Palascak, J E 1988. Platelet dysfunction and bleeding associated with beta-lactam antibiotics. The Journal of infectious diseases, 157 5, 1100-1Martelo,O.J.; Palascak,J.E. 1988. Platelet dysfunction and bleeding associated with beta-lactam antibiotics. Journal of Infectious Diseases, 157 5, 1100Lutomski,D.M.; Palascak,J.E.; Bower,R.H. 1987. Warfarin resistance associated with intravenous lipid administration Journal of Parenteral and Enteral Nutrition, 11 3, 316Miller, M A; Palascak, J E; Thompson, M R; Martelo, O J 1985. A modified SDS agarose gel method for determining factor VIII von Willebrand factor multimers using commercially available reagents. Thrombosis research, 39 6, 777-80Miller,M.A.; Palascak,J.E.; Thompson,M.R. 1985. A modified sds agarose gel method for determining factor viii von willebrand factor multimers using commercially available reagents Thrombosis Research, 39 6, 777Martinez, J; Keane, P M; Gilman, P B; Palascak, J E 1983. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Annals of the New York Academy of Sciences, 408 , 388-96Martinez, J; MacDonald, K A; Palascak, J E 1983. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood, 61 6, 1196-202Martinez,J.; Keane,P.M.; Gilman,P.B.; Palascak,J.E. 1983. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease Annals of the New York Academy of Sciences, Vol. 408 , 388Martinez,J.; MacDonald,K.A.; Palascak,J.E. 1983. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains Blood, 61 6, 1196Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. The New England journal of medicine, 303 8, 421-5Lusher, J M; Shapiro, S S; Palascak, J E; Rao, A V; Levine, P H; Blatt, P M 1980. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, 93 , 175-81Lusher,J.M.; Shapiro,S.S.; Palascak,J.E. 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor viii. a multicenter therapeutic trial New England Journal of Medicine, 303 8, 421Lusher,J.M.; Shapiro,S.S.; Palascak,J.E.; Rao,A.V.; Levine,P.H.; Blatt,P.M. 1980. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. Transactions of the Association of American Physicians, 93 , 175Martinez, J; Palascak, J E; Kwasniak, D 1978. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. The Journal of clinical investigation, 61 2, 535-8Martinez,J.; Palascak,J.E.; Kwasniak,D. 1978. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease Journal of Clinical Investigation, 61 2, 535Martinez,J.; Palascak,J.; Peters,C. 1977. Functional and metabolic properties of human asialofibrinogen Journal of Laboratory and Clinical Medicine, 89 2, 367Palascak, J E; Martinez, J 1977. Dysfibrinogenemia associated with liver disease. The Journal of clinical investigation, 60 1, 89-95Palascak, J E; Shapiro, S R 1977. Anti-factor VIII anamnesis after factor IX complex. The New England journal of medicine, 297 25, 1403Palascak,J.E.; Martinez,J. 1977. Dysfibrinogenemia associated with liver disease Journal of Clinical Investigation, 60 1, 89Palascak,J.E.; Shapiro,S.R. 1977. Anti-factor viii anamnesis after factor ix complex. New England Journal of Medicine, 297 25, 1403Martinez, J; Palascak, J E; Peters, C L 1975. Proceedings: Functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, 34 1, 324Martinez,J.; Palascak,J.E.; Peters,C.L. 1975. Proceedings: functional and metabolic studies of human asialofibrinogen. Thrombosis et diathesis haemorrhagica, 34 1, 324Krauss J.S.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. 12-11-1980. Treatment of Hemophilia with Prothrombincomplex Concentrates New England Journal of Medicine, 303 24, 1418Franco R.;Barker-Gear R.;Silberstein E.;Mayfield G.;Weiner M.;Palascak J.;Green R. 12-01-1992. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased i Advances in Experimental Medicine and Biology, 326 , 325-331Yasin Z.;Quick D.;Thiagarajan P.;Spoor D.;Caraveo J.;Palascak J. 10-13-1999. Light-chain paraproteins with lupus anticoagulant activity American Journal of Hematology, 62 2, 99-102Goedert J.J.;Siegel J.;Miller K.;Lederman M.M.;Thompson A.;Browning B.;Gamerman S.;McRedmond K.;Withycombe J.;Gruppo R.;Stack G.;Lusher J.;Percy L.;Nugent D.;McDaniel M.;Manno C.;Butler R.;Wade A.;Angiolillo A.;Luban N.L.C.;Guelcher C.;Tarantino M.;Greer S.;Gill J.;Nelson J.;White G.;Fried M.;Grimsley A.L.;DiMichele D.;Goldberg I.;French J.;Hibner S.;Steinberg J.;Faust S.;Key N.;Hannemann V.;Kessler C.M.;Lee A.E.;Eyster M.E.;Galli K.;Jenkins G.;Bernstein Z.P.;Belling L.;Shapiro A.;Halley M.;Noblet P.;Jardine L.;Laudenbach L.;Lipton R.;Pece C.;Leissinger C.A.;Schmidt C.;Carr M.;Nolte M.;Manco-Johnson M.;Giambartolomei S.;Rubin S.H.;Belliveau D.;Aledort L.;McCarthy J.;Lemons R.;Bleak S.;Kraut E.;Witkoff L.;Sexauer C.;Kiplinger F.;Thompson A.;Cooper C.;Britton H.;Cobb K.;Reimers H.J.;Bagato J.A.;Powell J.S.;Herr M.;Scott K.;Hutter J.;Damiano M.L.;Navarro W.;Roth J.;Palascak J.;Sherman K.;Heffner M.;DiPaolo J.;Lammer M.;Iyer R.;Matthew P.;Schwartz M.;Konkle B.;Vijayanathan N.;Dugdale M.;Lilley D.;Hoots K.;Brown D.;Ullman M.;Neff A.;Klintworth S.;Sabio H.;Smith A.;Karafoulidou A. 09-01-2005. Prevalence of conditions associated with human immunodeficiency and hepatits virus infections among Haemophilia, 11 5, 516-528Lusher J.M.;Shapiro S.S.;Palascak J.E.;Rao A.V.;Levine P.H.;Blatt P.M. 08-21-1980. Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII: A Multi New England Journal of Medicine, 303 8, 421-425Manco-Johnson M.J.;Bomgaars L.;Palascak J.;Shapiro A.;Geil J.;Fritsch S.;Pavlova B.G.;Gelmont D. 07-01-2016. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in Thrombosis and Haemostasis, 116 1, 58-68Sherman K.E.;Ke R.;Rouster S.D.;Abdel-Hameed E.A.;Park C.;Palascak J.;Perelson A.S. 07-01-2016. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs Haemophilia, 22 4, 543-548Tsuang W.;Navaneethan U.;Ruiz L.;Palascak J.B.;Gelrud A. 04-01-2009. Hypertriglyceridemic pancreatitis: Presentation and management American Journal of Gastroenterology, 104 4, 984-991Abildgaard C.F.;Lusher J.M.;Shapiro S.S.;Palascak J.E.;Levine P.H.;Blatt P.M. 03-12-1981. Hazards of Prothrombin-Complex Concentrates in Treatment of Hemophilia New England Journal of Medicine, 304 11, 670-671Parameswaran R.;Shapiro A.;Gill J.;Kessler C.;Abshire T.;Angiolillo A.;Boggio L.;Cohen A.;DiMichele D.;Hanna W.;Hoots K.;Hord J.;Key N.;Konkle B.;Kouides P.;Kurczynski E.;Marks P.;Palascak J.;Pipe S.;Ragni M.;Rivard G.;Shopnick R.;Tarantino M.;Valentino L.;Watts R.;White G. 03-01-2005. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysi Haemophilia, 11 2, 100-106Thompson A.R.;Gill J.C.;Ewenstein B.M.;Mueller-Velten G.;Schwartz B.A.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Bobrow S.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Green D.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Silver B.;Simpson T.;Stanek M.;Thompson A.R.;Tongol J.;Waterbury L.;White G.;Young R. 01-01-2004. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor Haemophilia, 10 1, 42-51Gill J.;Ewenstein B.;Thompson A.;Mueller-Velten G.;Schwartz B.;Abshire T.;Ambinder R.;Angiolillo A.;Arkel Y.;Beardsley D.;Benjamin R.;Binder M.;Charbel F.;Cooper B.;Cornell N.;Czapek E.;Eisenberg P.;Ewenstein B.;Garcia-Ortiz S.;Gastineau D.;Gill J.;Heggie G.;Heisel M.;Joist H.;Knupp C.;Lewis B.;Matthews D.;McKenna P.;Murukutla S.;Palascak J.;Penner J.;Powell J.;Ritter H.;Francisco R.;Shapiro A.;Simpson T.;Stanek M.;Thompson A.;Tongol J.;Waterbury L.;White G.;Young R. 01-01-2003. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate ( Haemophilia, 9 6, 688-695Martinez J.;Palascak J.;Peters C. 01-01-1977. Functional and metabolic properties of human asialofibrinogen The Journal of Laboratory and Clinical Medicine, 89 2, 367-377Cotto, M A; Lutomski, D M; Palascak, J E; Fant, W K; LaFrance, R J . Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study. JPEN. Journal of parenteral and enteral nutrition, 14 2, 201-3Lutomski, D M; Palascak, J E; Bower, R H . Warfarin resistance associated with intravenous lipid administration. JPEN. Journal of parenteral and enteral nutrition, 11 3, 316-8